Citations

Clear

40 citation(s) found for "Kim, Jung".

Abstract Fri086: CD38 NADase Suppresses Sulfite Oxidase (SUOX) and Activates Reverse Complex V to Promote Metabolic Remodeling in Endothelial Cells (ECs) Under Disturbed Flow
Ko, Kyung Ae , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Rivera, Luis Antonio, KIM, JUNG HYUN, Ostos-Mendoza, Kelia, Deswal, Anita, Pathania, Rajneesh , Morrell, Craig, Chini, Eduardo N. , Martin, James, Hamilton, Dale, Seeley, Erin, Burks, Jared, Brookes, Paul, LE, NHAT TU, Abe, Junichi, Kotla, Sivareddy , Lee, Jonghae , Chen, Weiqing , Hoang, O.N. , Zhang, Aijun , Imanishi, Masaki , Mendoza, Keila Carolina Ostos , Morrell, Craig , Shen, Ying , Hamilton, Dale J. , Burks, Jared K , Wang, Guangyu

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | July 28, 2026 | Volume: 46 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.46.suppl_1.fri086 Get It

Introduction: Atherosclerotic lesions preferentially form in arterial regions exposed to disturbed flow (DF), where ECs exhibit mitochondrial (mt) dysfunction, metabolic reprogramming, and senescence. Hippo pathway kinases LATS1/2 maintain EC homeostasis, but how DF–mediated LATS1/2 suppression drives EC metabolic remodeling remains unclear. Hypothesis: We propose that DF activates CD38, leading to mt dysfunction and metabolic reprogramming that promotes EC senescence and aberrant proliferation by LATS1/2 inhibition. Methods: EC-specific Lats1/2 knockout mice were generated using tamoxifen-inducible Cre systems, and DF was induced by partial carotid ligation. Murine and human plaques were analyzed using COMET™ immunofluorescence, and spatial metabolomics. Bioenergetic profiling included Seahorse XF analysis, 13 C-glucose/ 13 C-glutamine tracing, and pharmacologic modulation of CD38, mtROS, and ATP synthase. Results: Complete Lats1/2 deletion caused fatal edema and vascular leakage, while partial loss produced fragile, highly neovascularized plaques. Spatial proteomics revealed a CD38-driven senescence-associated stemness (SAS) phenotype under LATS1/2 deficiency. Metabolomics showed sulfite and taurine accumulation, consistent with SUOX deficiency. Mechanistically, CD38 suppressed SUOX, induced Complex V reverse-mode , increased succinate flux, and accelerated ATP consumption. Despite ATP depletion, glutamate metabolism and TCA cycle flux were enhanced, sustaining EC proliferation under energetic stress. LATS1/2 knockdown reduced mt respiratory capacity (lower OCR peak) without significantly increasing glycolysis, and DF suppressed both OCR and ECAR, indicating impaired energy metabolism under pathological shear stress. CD38 inhibition restored mt respiration and glycolytic capacity by preserving NAD, and rescuing LATS1/2 and DF-mediated defects. Blocking reverse-mode Complex V reduced DF- and LATS1/2-dependent EC senescence and proliferation. Conclusion: Complete LATS1/2 deletion causes fatal vascular leakage, while partial loss drives plaque formation with fragile neovessels through a CD38-dependent SAS phenotype. CD38 suppresses SUOX, induces Complex V reverse-mode , increases succinate flux, and accelerates ATP consumption, enabling EC proliferation despite energy stress. DF and LATS1/2 loss impair mt and glycolytic function, whereas CD38 inhibition restores mt respiration and reduces EC senescence and proliferation to prevent atherothrombosis in DF regions.
Colchicine Directly Targets Aldehyde Dehydrogenase 2 (ALDH2) to Suppress Radiation-Induced Senescence and Atherosclerosis
Abe, Jun‐ichi , Samanthapudi, Venkata Subrahman K, Chen, Weiqing , Tra, Ngoc Tuyet , Mejia, Gilbert F. , Hoang, Oanh, Rivera, Luis Antonio, Chu, Kun Yuan, Osawa, Masaki, Kim, J, Ko, Kyung Ae , Reddy, Anilkumar K. , Moreno, Silvia Fernanda López, Lenz, S., Mendoza, Keila Carolina Ostos , Sanchez, Edgardo, Herrmann, Joerg , Schadler, Keri , Manisty, Charlotte, Yusuf, Syed Wamique , Pathania, Rajneesh , Nead, Kevin T. , Hildebrandt, Michelle, Fuller, C David, Lin, Steve H., Le, Nhat‐Tu , Manisty, Charlotte , Hoang, O.N. , Kim, Jung Hyun , Hoang, Oanh , Abe, Jun-Ichi , Chen, Weiqing , Rivera, Luis Antonio , Kim, Jung Hyun , Lee, Jonghae , Li, Shengyu , Lenz, Stefania Assunto , Herrmann, Joerg , Schadler, Keri , Yvan-Charvet, Laurent , Ameri, Pietro , Yusuf, Syed Wamique , Burks, Jared K , Palaskas, Nicolas L , Fuller, Clifton D. , Koutroumpakis, Efstratios , Krishnan, Sunil , Wang, Guangyu , Kotla, Sivareddy

Mayo Clinic

No container title available | May 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.25.726409 Get It

Abstract Background Ionizing radiation (IR) accelerates atherosclerosis through induction of cellular senescence, DNA damage, defective efferocytosis, and dysregulation of clonal hematopoiesis (CH) drivers. Although low-dose colchicine reduces ischemic cardiovascular events in coronary artery disease, the precise molecular mechanisms underlying its vasculoprotective effects remain incompletely defined, and whether it mitigates radiation-associated vascular injury is unknown. Methods Bone marrow–derived macrophages (BMDMs) were pretreated with low-dose colchicine and exposed to 2 Gy IR. Molecular effects were assessed by RNA-seq, immunoblotting, and molecular docking. In vivo effects were tested in a partial carotid ligation (PLCL) model using spatial proteomics. Human monocyte-derived macrophages (HMDMs) from thoracic malignancy patients were analyzed before and after radiation therapy (RT). Results Low-dose colchicine suppressed IR-induced macrophage senescence signaling while preserving NRF2 activity. In a cell-free assay, colchicine directly activated aldehyde dehydrogenase 2 (ALDH2) in a dose-dependent manner (EC 50 1–5 nM), identifying ALDH2 as a direct molecular target of colchicine. Following irradiation, colchicine restored ALDH2, reduced mitochondrial (mt)ROS - dependent p90 ribosomal S6 kinase ( p90RSK ) activation and lipid peroxidation, preserved TET2 and DNMT3A expression, and rescued impaired efferocytosis while preventing nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP) depletion. These protective effects were ALDH2-dependent, as they were lost with ALDH2 inhibition or depletion and were mimicked by pharmacologic ALDH2 activation. In vivo, colchicine attenuated radiation-induced atherosclerosis and macrophage senescence-associated stemness (SAS). Consistently, macrophages from patients after RT showed reduced ALDH2 with increased mtROS, lipid peroxidation, and senescence. Conclusion These findings identify ALDH2 as a previously unrecognized molecular target of colchicine that links mitochondrial redox control to suppression of radiation-induced macrophage senescence and atherosclerosis and may contribute to the efficacy of low-dose colchicine in cardiovascular disease.
Rapid reduction in global chromatin loop size after acute STAG2 reconstitution in human cancer cells
Yang, Tianyi , Kim, Jung-Sik, Mellows, Clara , Xu, Wanying, Ya, Alvin , Sadzewicz, Lisa, Tallon, Luke, Sarkaria, Jann, Jin, Fulai, Waldman, Todd, Kim, Jung-Sik , Xu, Wanying, Sadzewicz, Lisa , Tallon, Luke J. , Sarkaria, Jann N. , Jin, Fulai , Waldman, Todd

Mayo Clinic

No container title available | May 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.26.727913 | PMID 42244697 Get It

ABSTRACT Truncating mutations in the tumor suppressor STAG2 , which encodes a component of the cohesin complex, are prevalent across diverse human cancers. Here, we report that acute reconstitution of physiological STAG2 levels in STAG2 -mutant human glioblastoma multiforme cancer cells triggers a rapid reduction in the size of chromatin loops genome-wide. Despite this global change in chromatin loop size, early transcriptional responses to STAG2 restoration are limited to a small number of genes, most of which are induced by STAG2 reconstitution. Notably, the growth-suppressor EFEMP1 (Fibulin-3), a secreted glycoprotein that functions as an extracellular matrix-associated inhibitor of glioblastoma growth and invasion, was the only gene consistently induced across all experimental models. The most robust and conserved STAG2-induced genes all reside within intense chromatin loops whose anchors and overall intensity did not appear to change in response to STAG2 reconstitution. These findings suggest that inactivating mutations of STAG2 promote neoplastic transformation by alleviating a restriction on chromatin loop size, allowing for an expanded range of chromatin interactions that disrupts the maintenance of a tumor-suppressive transcriptome.
LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis
Kotla, Sivareddy , Ko, Kyung Ae , Chen, Weiqing , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Li, Shengyu , Lee, Hani , Zhang, Angie, Cho, Min Soon , Schadler, Keri L., Rivera, Luis Antonio, Samperio, Kay Carlene Tavares, Kim, Jung Hyun , Mendoza, Keila Carolina Ostos , Mariscal-Reyes, Karla N., Deswal, Anita, Fujiwara, Keigi , Koutroumpakis, Efstratios, Gi, Young Jin , Pathania, Rajneesh , Morrell, Craig N. , Lorenzi, Philip L. , Tan, Lin, Mahmud, Iqbal, Chini, Eduardo N., Herrmann, Joerg , Vasquez, Hernan G., Shen, Ying H. , Martin, James F. , Xu, Haodong, Le, Nhat‐Tu , Zhang, Aijun , Hoang, O.N. , Kim, Jung Hyun , Lee, Jonghae , Chen, Weiqing , Samanthapudi, Venkata Subrahmanya Kumar , Hoang, Oanh , Mejia, Gilbert , Li, Shengyu , Lee, Hani , Zhang, Aijun , Cho, Min Soon , Schadler, Keri , Rivera, Luis Antonio , Kim, Jung Hyun , Ostos-Mendoza, Keila C , Deswal, Anita M , Cooke, John P , Fujiwara, Keigi , Palaskas, Nicolas L , Koutroumpakis, Efstratios , Gi, Young Jin , Morrell, Craig , Lorenzi, Philip L , Madhmud, Iqbal , Hanssen, Nordin M J , Afshar-Kharghan, Vahid , Hamilton, Dale J , Yvan-Charvet, Laurent , Chini, Eduardo Nunes , Herrmann, Joerg , Shen, Ying H , Martin, James F , Seeley, Erin , Burks, Jared K , Brookes, Paul S , Wang, Guangyu , Le, Nhat-Tu , Abe, Jun-Ichi , Kotla, Sivareddy , Lee, Jonghae , Imanishi, Masaki , Cooke, John P. , Tan, Lin, Hamilton, Dale J. , Chini, Eduardo N. , Wang, Guangyu

Mayo Clinic

Circulation Research | May 27, 2026 | Volume: 139 | Issue: 2 | Pages: No page available

10.1161/circresaha.125.327427 | PMID 42200276 Get It

BACKGROUND: Atherothrombosis, which underlies most acute coronary syndromes and is driven by intraplaque thrombosis, preferentially occurs in regions of disturbed blood flow (d-flow). Although LATS1/2 (large tumor suppressor kinases 1 and 2) are known regulators of endothelial mechanotransduction, the mechanisms by which d-flow connects endothelial senescence, proliferation, and intraplaque thrombosis remain poorly understood. METHODS: We investigated endothelial cell (EC)-specific roles of Lats1/2 using inducible EC-specific knockout mice in a partial carotid ligation model. Spatial multiomics of human and mouse plaques was performed using imaging mass cytometry, COMET sequential immunofluorescence, and spatial metabolomics. RESULTS: Tamoxifen-induced deletion of both Lats1 and Lats2 (homozygous) in ECs caused fatal edema and increased vascular permeability. In contrast, Lats1 het ( ± ) / Lats2 homo ( −/−) -EC-specific knockout mice survived and developed spontaneous atherothrombotic plaques with neovascularization. Spatial proteomics revealed that LATS1/2 loss induced a senescence-associated stemness phenotype driven by CD38 upregulation. Spatial metabolomics showed sulfite and taurine accumulation, indicating SUOX (sulfite oxidase) deficiency. CD38 suppressed SUOX, demonstrated a switch into the reverse mode of mitochondrial complex V, increased succinate dehydrogenase activity, and promoted ATP consumption. Despite ATP depletion, glutamate metabolism and the citric acid cycle flux increased, sustaining EC proliferation under energetic stress. This senescence-associated stemness state promoted both proliferation and senescence, leading to fragile, leaky neovessels and intraplaque thrombotic lesions. Pharmacological CD38 inhibition attenuated these phenotypes. Similar EC states were observed in human plaques. CONCLUSIONS: Loss of Lats1/2 in ECs induces a CD38-associated senescence-associated stemness-like phenotype that promotes intraplaque thrombosis through mitochondrial metabolic reprogramming, including changes consistent with reverse-mode operation of mitochondrial complex V. These findings define a mechanistic link between disturbed flow, endothelial metabolic reprogramming, and intraplaque thrombosis and hemorrhage.
Immune Checkpoint Inhibitor-Induced Cardiovascular Disease: The Role of Accelerated Senescence in Vascular Dysfunction
Casso-Chapa, Bernardo , Paniagua-Bojorges, Angelica , Palaskas, Nicolas L., Nead, Kevin T. , Samanthapudi, Venkata S.K., Mejia, Gilbert, Kim, Jung Hyun , Deswal, Anita, Herrmann, Joerg, Wang, Guangyu, Kirkland, James L., Krishnan, Sunil, Shen, Ying Hu, Yusuf, Syed Wamique , Iliescu, Cezar, González, Norma Alicia Vazquez, Mendoza, Keila Carolina Ostos , Hanssen, Nordin M.J., Winther, M. De, Yvan-Charvet, L., Nurieva, Roza I., Schadler, Keri , Koutroumpakis, Efstratios, Cooke, J., Le, Nhat-Tu, Abe, Jun-ichi, Kim, Jung Hyun , Palaskas, Nicolas L , Lee, Jonghae , Hoang, O.N. , Lin, Steven H. , Deswal, Anita M , Herrmann, Joerg , Kirkland, James L. , Krishnan, Sunil , Yusuf, Syed Wamique , Jain, Abhishek , Hanssen, Nordin M J , Winther, Menno P.J. de , Yvan-Charvet, Laurent , Nurieva, Roza , Schadler, Keri , Koutroumpakis, Efstratios , Cooke, John P , Kotla, Sivareddy

Mayo Clinic

Antioxidants & Redox Signaling | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15230864251410546 | PMID 42850906 Get It

Significance: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by reactivating antitumor immunity and improving outcomes across multiple malignancies. Yet, clinical observations and preclinical studies suggest that ICIs may increase long-term cardiovascular disease risk, including hypertension, atherosclerosis, and thrombosis. The underlying mechanisms remain incompletely defined, highlighting the need for focused investigation into the vascular consequences of immune activation. Recent Advances: ICI-induced immune activation disrupts vascular and immune homeostasis through persistent production of reactive oxygen species (ROS), mitochondrial dysfunction, and accumulation of cell-free DNA (cfDNA). Sustained T-cell activation enhances ROS generation, driving DNA damage and senescence in both endothelial and immune cells. ICIs may also promote endothelial-to-mesenchymal transition (EndoMT) through chronic oxidative and inflammatory signaling, contributing to fibrosis, vascular stiffness, and chronic inflammation. Transforming growth factor-beta, although immunosuppressive in many contexts, can drive profibrotic and EndoMT programs within the vasculature. Other cytokines and regulators, including interleukin-17 and regulator of calcineurin 1, have been implicated in vascular remodeling, atherosclerosis, and hypertension. Critical Issues: The relative roles of ROS, mitochondrial dysfunction, cfDNA-driven inflammation, and EndoMT in ICI-associated vascular senescence remain unclear. While inflammation-induced vascular damage is well-recognized, direct ICI-specific mechanisms require stronger evidence. How senescent endothelial and immune cells influence therapy resistance and remodeling of the tumor microenvironment also remains to be defined. Future Directions: Mitochondrial and cytosolic ROS sources—arising from electron leakage during oxidative phosphorylation and NADPH oxidases activity—shape immune signaling and sustain T-cell activation during checkpoint blockade. The DNA damage response kinases ataxia-telangiectasia mutated and ATM- and Rad3-related, activated by oxidative and replicative stress, engage p53-dependent senescence pathways in endothelial and immune cells. Future studies should evaluate biomarkers such as cfDNA and thrombospondin-1 and explore senescence-targeting or redox-modulating interventions that may alleviate cardiovascular toxicity without diminishing antitumor efficacy. This review outlines mechanistic pathways linking ICIs to vascular dysfunction and senescence, integrating preclinical data with emerging clinical insights. It distinguishes established processes from ICI-specific hypotheses and identifies key gaps requiring clinical validation. Antioxid. Redox Signal. 00, 000–000.
SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk
Moreno, Sira , Lenz, S., Casso-Chapa, Bernardo , Paniagua-Bojorges, Angelica , Kim, Jung Hyun , Palaskas, Nicolas L. , Nead, Kevin T. , Samanthapudi, Venkata Subrahman K, Mejia, Gilbert, Hoang, O.N. , Lee, Jonghae , Lin, Steven H. , Herrmann, Joerg , Yusuf, Syed Wamique , Iliescu, Cezar , Beinart, Noah , Manisty, Charlotte , Fukai, Tohru , Ameri, Pietro , Nurieva, Roza , Hildebrandt, Michelle A T, Schadler, Keri , Le, Nhat‐Tu , Abe, Jun‐ichi , López Moreno, Silvia Fernanda , Hoang, Oanh , Iliescu, Cezar A , Fukai, Tohru , Ameri, Pietro , Schadler, Keri , Le, Nhat-Tu , Abe, Jun-Ichi , Lin, Steven H , Palaskas, Nicolas L , Nead, Kevin T , Lee, Jonghae , Kim, Jung Hyun , Lenz, Stefania Assunto, Wang, Guangyu , Yusuf, Syed Wamique , Ushio‐Fukai, Masuko , Hildebrandt, Michelle A.T. , Koutroumpakis, Efstratios , Kotla, Sivareddy , Lenz, Stefania Assunto

Mayo Clinic

Antioxidants | November 21, 2025 | Volume: 14 | Issue: 12 | Pages: 1388

10.3390/antiox14121388 | PMID 41462587 Get It

Src homology 2-domain containing protein tyrosine phosphatase 2 (SHP2), encoded by the Ptpn11 gene (Tyrosine-protein phosphatase non-receptor type 11), is a key downstream effector of PD-1/PD-L1 signaling and is likely important, in addition to immune modulation, in tumor development and vascular homeostasis. SHP2 conveys PD-1 mediated inhibitory signaling in T cells, and is emerging as a therapeutic target. Importantly, there is an association between immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs), and cardiovascular complications, underscoring the need to understand SHP2’s role in these processes. This review aims to summarize current knowledge on SHP2/PTPN11 biology, its role in immune regulation, cancer progression, and vascular homeostasis, and to discuss emerging therapeutic strategies targeting this pathway. The concept of using SHP2 inhibitors with immune checkpoint inhibitors (ICIs) is being investigated to address ICI resistance and to improve anti-tumor efficacy substantially. SHP2 is also being studied in non-cancer cell contexts, and signaling responses can differ by large magnitudes depending on the biological context and stimuli. Under normal circumstances, SHP2 promotes vascular homeostasis in endothelial cells (ECs) and myeloid cells and inhibits inflammation, and the reduction in SHP2 activity by oxidative stress, such as in atherosclerosis or diabetes, upregulates inflammation. In contrast, in response to radiation, the fibrotic response and subsequent lung injury were increased by endothelial SHP2 induction via Notch-Jag1 signaling. Vascular smooth muscle cells SHP2 act as a pro-atherogenic effector by enhancing ERK/MAPK signaling, and the upregulation of mitochondria localized SHP2 can also induce cellular senescence-associated inflammation by upregulating mitochondrial reactive oxygen species. Taken together, the two opposite signaling effects of SHP2 suggest that both the immune and vascular system responses appear to be more modulated by the redox, cell, and compartment-specific signaling of SHP2. More studies are needed for mitigating cardiovascular toxicity to patients, particularly with ICI-based treatment regimens.
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease
Lu, Ming , Collins, Emily C. , Shcherbinin, Sergey, Ellinwood, Amy K., Brooks, Dawn A. , Knopman, David S., Sims, John R. , Mintun, Mark A., Kim, Min Jung , Ellinwood, Amy K. , Yokoi, Yuma , Hansson, Oskar

Mayo Clinic

JAMA Neurology | October 13, 2025 | Volume: 82 | Issue: 12 | Pages: 1251

10.1001/jamaneurol.2025.3869 | PMID 41082199 Get It

Importance Accumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. Objective To assess the correlation of posttreatment amyloid levels with clinical outcomes and biomarkers in AD. Design, Setting, and Participants This was a post hoc exploratory analysis from the randomized, placebo-controlled phase 3 trial, TRAILBLAZER-ALZ 2, conducted June 2020 through April 2023 at 277 medical research centers/hospitals in 8 countries. A total of 8240 participants aged 60 to 85 years with early symptomatic AD with amyloid and tau pathology based on positron emission tomography (PET) imaging were assessed for eligibility. Of these, 6504 participants were excluded predominantly due to inadequate amyloid or tau pathology. The current analysis included 1582 participants (766 in the donanemab group and 816 in the placebo group) with baseline and at least 1 posttreatment assessment. Data analysis took place from July 2024 to March 2025. Interventions Participants were randomized 1:1 to receive donanemab (700 mg for the first 3 doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks, with outcomes assessed through 76 weeks. Main Outcomes and Measures Participants were categorized into 1 of 10 groups (deciles) based on their lowest amyloid value observed posttreatment. Clinical progression was assessed via changes in integrated Alzheimer’s Disease Rating Scale (iADRS) and Clinical Dementia Rating–Sum of Boxes (CDR-SB) scores. Plasma biomarkers measured included phosphorylated tau 217 (p-tau217), p-tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Correlations between the median amyloid level in each decile were assessed with 76-week least-squares mean changes in each outcome and biomarker. Results Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo. The mean (SD) age was 72.9 (6.2) years, and 900 participants (56.9%) were female. Participants who received donanemab had lower posttreatment amyloid values than those in the placebo group. Across the trial population, lower posttreatment amyloid levels were correlated with slower clinical progression as measured by iADRS score ( R 2 , 0.73 [95% CI, 0.37-0.97]) and CDR-SB score ( R 2 , 0.87 [95% CI, 0.70-0.97]) and with decreases in p-tau217 ( R 2 , 0.86 [95% CI, 0.73-0.97]), p-tau181 ( R 2 , 0.88 [95% CI, 0.77-0.97]), and GFAP ( R 2 , 0.87 [95% CI, 0.76-0.97]). There was no correlation between posttreatment amyloid value and NfL ( R 2 , 0.03 [95% CI, 0.00-0.54]). Conclusions and Relevance The findings in this secondary analysis of a randomized clinical trial demonstrating a correlation between posttreatment amyloid plaque level and clinical benefit support amyloid plaque removal as the mechanism of action for donanemab treatment and the level of amyloid plaque as a potential surrogate biomarker in amyloid-targeting therapies. Trial Registration ClinicalTrials.gov Identifier: NCT04437511
Lower Trapezius Tendon Transfer Using Achilles Tendon Allograft Effectively Restores Function After Failed Superior Capsular Reconstruction
Marigi, Erick M. , Baek, Chang Hee , Lim, Chaemoon , Baek, Gyuna , Elhassan, Bassem T. , Marigi, Erick , Kim, Bo Taek , Kim, Jung-Gon

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | July 22, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2025.101222 | PMID 41583800 Get It

Purpose To evaluate the clinical outcomes of lower trapezius tendon (LTT) transfer using an Achilles tendon allograft in patients with failed superior capsular reconstruction (SCR). Methods A retrospective therapeutic review was conducted on patients who underwent LTT transfer using an Achilles tendon allograft after SCR failure between January 2018 and May 2020. The inclusion criteria encompassed both structural and functional failures of SCR in patients with minimal glenohumeral arthritis and a minimum follow‐up of 2 years. Exclusion criteria were insufficient clinical data or loss to follow‐up. Clinical outcomes were assessed preoperatively and at final follow‐up using the visual analog scale (VAS), subjective shoulder value (SSV), Constant score, American Shoulder and Elbow Surgeons (ASES) score, and range of motion (ROM). Results Eighteen patients were included, with a mean follow‐up of 42.5 months (range: 24‐62 months). All outcome measures demonstrated statistically significant improvement: VAS scores improved from 5.9 ± 1.3 to 1.8 ± 1.4; SSV scores improved from 18.0 ± 9.1 to 61.4 ± 18.5; Constant score improved from 33.3 ± 5.3 to 65.5 ± 17.4; and ASES score improved from 38.5 ± 5.2 to 67.1 ± 17.7 (all P < .001). On the basis of the minimal clinically important difference (MCID) using a 0.5 SD distribution‐based method, clinically meaningful improvements were observed in 88.9% of patients for VAS and ASES scores, and 94.4% for Constant and SSV scores. ROM gains included forward elevation (73° to 120°), abduction (57° to 93°), and external rotation (−22° to 40°). At final follow‐up, 77.8% of patients had resumed occupational activities, and 61.1% returned to sports. Four patients (22.2%) required conversion to reverse shoulder arthroplasty. Conclusions LTT transfer using an Achilles tendon allograft following failed SCR yields significant improvements in pain relief, functional outcomes, and ROM. LTT transfer using an Achilles tendon allograft following failed SCR may offer a potential treatment option, particularly in younger, active patients who seek to preserve native shoulder anatomy and function. Level of Evidence Level IV retrospective case series.
Downregulation of LATS1/2 Drives Endothelial Senescence-Associated Stemness (SAS) and Atherothrombotic Lesion Formation
Kotla, Sivareddy , Ko, Kyung Ae , Chen, Weiqing , Samanthapudi, Venkata Subrahman K, Hoang, O.N. , Mejia, Gilbert, Li, Shengyu , Schadler, Keri , Rivera, Luis Antonio, Samperio, Kay Carlene Tavares, Kim, Jung Hyun , Mendoza, Keila Carolina Ostos , Mariscal-Reyes, Karla N., Fujiwara, Keigi , Gi, Young Jin , Pathania, Rajneesh , Morrell, C Jane, Lorenzi, Philip L. , Tan, Lin , Chini, Eduardo N. , Herrmann, Joerg, Vasquez, Hernan G., Shen, Ying H. , Martin, James F. , Le, Nhat‐Tu , Kim, Jung Hyun , Lee, Jonghae , Chen, Weiqing , Hoang, Oanh , Mejia, Gilbert , Schadler, Keri , Ostos-Mendoza, Keila C , Deswal, Anita M , Cooke, John P , Fujiwara, Keigi , Palaskas, Nicolas L , Koutroumpakis, Efstratios , Lorenzi, Philip L , Madhmud, Iqbal , Hanssen, Nordin M J , Shen, Ying H , Martin, James F , Seeley, Erin , Burks, Jared K , Brookes, Paul S , Wang, Guangyu , Le, Nhat-Tu , Abe, Jun-Ichi , Kotla, Sivareddy , Kim, Jung Hyun , Lee, Jonghae , Rivera, Luis Antonio, Imanishi, Masaki , Cooke, John P. , Morrell, Criag, Yvan-Charvet, Laurent , Herrmann, Joerg, Xu, Haodong , Wang, Guangyu

Mayo Clinic

No container title available | June 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.19.660635 | PMID 40667385 Get It

ABSTRACT Background Atherothrombosis, the main event leading to acute coronary syndrome (ACS), is strongly linked to disturbed blood flow (d-flow) regions. Although the involvement of the Hippo pathway and its kinases Large Tumor Suppressor Kinase 1and 2 (LATS 1 and 2) in mechanical stress responses is known, the mechanisms by which d-flow simultaneously induces senescence, proliferation, and atherothrombosis remain unclear. Methods The role of endothelial cells (EC)-specific LATS1/2 was examined using EC specific knock-out (EKO) mice in a partial left carotid ligation (PLCL) model. Plaque spatial multi-omics analysis was performed by integrating imaging mass cytometry, sequential immunofluorescence (COMET™), and spatial metabolomics at the single-cell level in human and mouse atherosclerotic plaques. Results In tamoxifen-inducible Lats1 homo( -/- ) / Lats2 homo( -/- ) EC-specific knockout (EKO) mice, deletion of LATS1/2 induced by tamoxifen led to fatal outcomes, characterized by severe systemic edema and markedly increased vascular permeability. In contrast, Lats1 het(+ /- ) / Lats2 homo( -/- ) -EKO mice survived and developed atherothrombotic plaques exhibiting neovascularization even without further additional dietary or genetic intervention. Spatial proteomics analysis revealed that LATS1/2 depletion in ECs triggered a senescence-associated stemness (SAS) phenotype, primarily driven by CD38 upregulation. Complementary spatial metabolomics profiling demonstrated a significant increase in sulfite and taurine within LATS1/2-deficient plaques, indicating lowered sulfite oxidase (SUOX) activity. Mechanistically, CD38 upregulation was found to suppress SUOX expression, induce the reverse mode of mitochondrial complex V, and increase succinate dehydrogenase (SDH) activity along with ATP consumption. Paradoxically, despite ATP depletion, this metabolic disturbance enhanced glutamate metabolism and the tricarboxylic acid (TCA) cycle, sustaining EC proliferation under energetically stressed conditions. The combined effect of LATS1/2 deletion and CD38 activation established a unique EC phenotype defined by increased SAS, leading to proliferation, senescence, and eventual cell death. These pathological processes culminated in the formation of atherothrombotic plaques, which were attenuated by inhibition of CD38. Notably, a similar phenotype—marked by metabolically active ECs—was observed in human atherothrombotic plaques, suggesting translational relevance. Conclusion Loss of LATS1/2 in ECs induces SAS state that promotes excessive EC proliferation, senescent cell accumulation, and the development of structurally fragile, leaky neo vessels—hallmarks of atherothrombotic lesions. CD38-mediated SUOX deficiency further amplifies this pathological process by inducing mitochondrial dysfunction, depleting ATP, and triggering compensatory upregulation of glutamate and TCA cycle metabolism. These findings identify a novel LATS1/2–CD38–SUOX axis in ECs that orchestrates SAS-driven atherothrombosis. Targeting CD38 may represent a promising therapeutic strategy to mitigate vascular dysfunction and plaque instability in high-risk ACS patients. Graphical abstract Under normal physiological conditions, LATS1/2 and Lamin A work together to suppress CD38 expression. Lamin A binds directly to the CD38 promoter to repress transcription, and LATS1/2 interact with Lamin A to reinforce this suppression. This collaboration helps maintain low CD38 activity and preserves cellular NAD⁺ levels. However, under disturbed flow (d-flow), both LATS1/2 and Lamin A are downregulated. The loss of this dual repression leads to increased CD38 NADase expression. Elevated CD38 accelerates NAD⁺ consumption, causing NAD⁺ depletion—a hallmark of cellular senescence. Reduced NAD⁺ disrupts key metabolic and stress-response pathways, contributing to the onset of the senescent state. At the same time, CD38 suppresses sulfite oxidase (SUOX), leading to sulfite accumulation and mitochondrial redox imbalance. This shift activates the reverse mode of mitochondrial Complex V, which decreases ATP production and increases mitochondrial ROS, intensifying metabolic and oxidative stress in endothelial cells (ECs). In response, ECs compensate by upregulating succinate dehydrogenase (SDH), enhancing TCA cycle activity and glutamate metabolism. This metabolic adaptation provides the biosynthetic building blocks needed for cell growth and proliferation. As a result, ECs adopt a paradoxical phenotype: they show classical features of stress-induced senescence (such as NAD⁺ depletion, oxidative stress, and cell cycle arrest signals), while simultaneously undergoing metabolic activation and proliferation, also mediated by YAP. This defines a non-canonical endothelial program known as senescence-associated stemness (SAS), characterized by the formation of abnormal, proliferative, yet fragile neovessels. These dysfunctional vessels contribute to atherothrombosis, setting this process apart from the more stable lesions typical of conventional atherosclerosis.
Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor
Nelson, Alexander T. , Watson, David , Chen, Kenneth , Olson, Damon R. , Stall, Jennifer N., Devins, Kyle M. , Young, Robert H. , Kamihara, Junne , Mallinger, Paige, Kim, Jung , Hatton, Jessica N. , Schneider, Dominik T. , Harris, Anne K. , Dehner, Louis P. , Schultz, Kris Ann P. , Watson, Dave , Chen, Kenneth S , Mallinger, Paige H R , Messinger, Yoav H , Frazier, A Lindsay , Stewart, Douglas R , Harris, Anne K , Dehner, Louis P , Hill, Dana Ashley , Schultz, Kris Ann P , Olson, Damon R , Schneider, Dominik T , Devins, Kyle M , Messinger, Yoav H.

Mayo Clinic

JCO Precision Oncology | April 23, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00902 | PMID 40267387 Get It

PURPOSE Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, representing <0.5% of all ovarian tumors. We analyze the role of germline DICER1 status in outcomes of ovarian SLCT. METHODS Patients with SLCT were enrolled in the International Pleuropulmonary Blastoma/ DICER1 Registry and/or the International Ovarian and Testicular Stromal Tumor Registry. Medical records were systematically abstracted, and those with known germline DICER1 status were selected for analysis. RESULTS Of 162 patients with SLCT, 60% had a germline DICER1 pathogenic or likely pathogenic (P/LP) variant. The adjusted 3-year recurrence-free survival (RFS) was 87.2% (95% CI, 79.4 to 95.8) for patients with a germline DICER1 P/LP variant compared with 78.1% (95% CI, 66.4 to 91.9) for those without a germline DICER1 P/LP variant ( P = .043). The adjusted 3-year and 5-year overall survival (OS) was 93.9% (95% CI, 87.3 to 100.0) for those with a germline DICER1 P/LP variant compared with the 3-year OS of 91.3% (95% CI, 83.4 to 100.0) and the 5-year OS of 78.2% (95% CI, 63.8 to 95.9) for those without a germline DICER1 P/LP variant ( P = .021). Among patients with a germline DICER1 P/LP variant, the risk of a subsequent, nonrecurrent event was 36.2% (95% CI, 21.4 to 48.1) within 10 years. Previous/concurrent and subsequent neoplasms were rare among those without a germline DICER1 P/LP variant. CONCLUSION This cohort study of patients with SLCT demonstrated that those with germline DICER1 P/LP variants had superior RFS and OS even when adjusting for other prognostic factors. Beyond prognostic implications of a germline DICER1 P/LP variant, germline testing helps identify patients at risk of subsequent neoplasms, including metachronous SLCT.